Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K33/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220008458TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE
US 13.01.2022
Int.Class A61K 33/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
30Zinc; Compounds thereof
Appl.No 17365695 Applicant American Regent, Inc. Inventor Gopal Anyarambhatla

Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 μg to about 4,000 μg of zinc, about 40 μg to about 400 μg of copper, from about 4 μg to about 90 μg of selenium, or from about 1 μg to about 80 μg of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

2.20220008460TREATING MALE INFERTILITY SECONDARY TO SPERM OXIDATIVE STRESS
US 13.01.2022
Int.Class A61K 33/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
30Zinc; Compounds thereof
Appl.No 17476801 Applicant Parviz Gharagozloo Inventor Parviz Gharagozloo

A profertility composition for administration to infertile men with sperm oxidative stress is disclosed. The composition comprises a unique combination of a pharmaceutically acceptable vitamin E, vitamin D, vitamin C, selenium, zinc, folate, lycopene, at least one carnitine source, and optionally Coenzyme Q10. Also disclosed are methods of treating male infertility.

3.20220008459OPHTHALMIC FORMULATION AND METHODS OF USE
US 13.01.2022
Int.Class A61K 33/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
30Zinc; Compounds thereof
Appl.No 17371303 Applicant Abdelhamid Muhammad AlQallawi Inventor Abdelhamid Muhammad AlQallawi

Provided herein are methods and compositions for an eye drop and medication. Accordingly, the eye drop and medication have the potential for the provision of and pioneering non-surgical treatment of eye conditions.

4.WO/2022/008902METHOD FOR TREATING A GD2-POSITIVE CANCER
WO 13.01.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/GB2021/051721 Applicant EUSA PHARMA (UK) LIMITED Inventor LODE, Holger Nikolaus
A method of treating a newly diagnosed neuroblastoma in a patient by administering chimeric anti-GD2 antibody dinutuximab beta to the patient in combination with induction chemotherapy. The chimeric anti-GD2 antibody dinutuximab beta is administered at a cumulative dose of up to 500 mg/m2, and/or in a dose of up to 100 mg/m2 per cycle during one or more cycles of induction chemotherapy, and/or at a treatment density of up to 5 mg/m2/day.
5.20220008357EYE HEALTH SUPPLEMENT WITH CURCUMIN
US 13.01.2022
Int.Class A61K 31/065
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
065Diphenyl-substituted acyclic alcohols
Appl.No 17448513 Applicant QH Holdings (Oregon), Inc. Inventor James Stringham

An eye health supplement and methods of using the eye health supplement are disclosed.

6.WO/2022/006632DENTAL COMPOSITIONS
WO 13.01.2022
Int.Class A61K 6/838
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
6Preparations for dentistry
80Preparations for artificial teeth, for filling teeth or for capping teeth
831comprising non-metallic elements or compounds thereof, e.g. carbon
838Phosphorus compounds, e.g. apatite
Appl.No PCT/AU2021/050728 Applicant BIODENTAL REMIN LTD Inventor MCINTOSH, Ian
The present invention relates to a composition comprising calcium sucrose phosphate – calcium phosphate (CSP-ICP) complexes and between 0.5wt% and 5wt% calcium chloride (CaCl2). The present invention also relates to a method for preparing the composition, a method for using the composition and use of the composition for preparing a medicament.
7.WO/2022/010337METHOD FOR REDUCING THE INCIDENCE AND PREVALENCE OF HUMAN PAPILLOMAVIRUS (HPV) AND FOR PROVIDING PROTECTION AGAINST SEXUALLY TRANSMITTED INFECTIONS
WO 13.01.2022
Int.Class A61K 33/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
Appl.No PCT/MX2021/000022 Applicant SANDERS ESPARZA, Eleonora Inventor SANDERS ESPARZA, Eleonora
Methods comprising the insertion of a uterine cervical device in the lower part of the uterine cavity and endocervix to reduce the incidence of human papillomavirus, mainly types 16 and 18, in women, thereby preventing the development of uterine cervical cancer; to modify the cervical microbiota; to increase leukocytes; and to protect women against sexually transmitted infections.
8.WO/2022/008943METHOD FOR CARRYING OUT A FASTING COURSE FOR SERIOUSLY ILL PATIENTS
WO 13.01.2022
Int.Class A61K 33/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
Appl.No PCT/IB2020/000780 Applicant MARTYNOVA, Elena Anatol'evna Inventor MARTYNOVA, Elena Anatol'evna
The invention relates to medicine and can be used for seriously ill patients undergoing a fasting course aiming to achieve pain relief. The claimed method consists in excluding food and liquid intake for several days, and in adhering to a vegetarian diet based on dietetic food prior to the beginning of the fasting course. First, specimens of live strains of typical E. coli and non-lactose-fermenting E. coli are taken from a patient and are grown under artificial conditions, the strains produced being stored for the duration of the fasting period; during the patient’s feeding periods, the grown cultures of typical E. coli and non-lactose-fermenting E. coli are then administered to the patient; on the first occasion of bowel opening, a specimen is taken, and the level of E. coli bacilli is analysed in order to determine whether or not it corresponds to normal levels, where a normal level is considered to be: typical E. coli 107-108 CFU/g of faeces, non-lactose-fermenting E. coli <105 CFU/g of faeces, haemolytic E. coli – 0; and in case of deviation from the normal level, when the level of E. coli is insufficient, the administration of the corresponding strains of typical E. coli and/or non-lactose-fermenting E. coli to the patient is repeated; and, when the level of E. coli is excessive, the corresponding strains of typical E. coli and/or non-lactose-fermenting E. coli are excluded in the next food intake; if haemolytic E. coli is detected, oral rehydration is prescribed.
9.WO/2022/010683TOPICAL VITAMIN C COMPOSITION
WO 13.01.2022
Int.Class A61K 31/185
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
Appl.No PCT/US2021/039388 Applicant TOPIX PHARMACEUTICALS, INC. Inventor HERNANDEZ, Steven, M.
Disclosed in certain embodiments herein is a topical composition that delivers advanced environmental protection to the skin, brightens the complexion of the skin, and/or delivers anti-aging benefits to the skin by treating ntrinsic and/or extrinsic factors associated with the appearance and health of the skin. The topical composition may be an emulsion of an aqueous phase and an oily phase, or other two-phase system, that includes an ascorbate component and an antioxidant system that includes green tea polyphenols. Also disclosed herein are methods of administering the topical compositions described herein for treating a skin of a subject for effects of radical induced damage, atmospheric aging, and as part of a variety of dermatological procedures.
10.20220008454Silicic Acids for Use in the Treatment of Periodontitis
US 13.01.2022
Int.Class A61K 33/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
Appl.No 17281811 Applicant Bio Minerals N.V. Inventor Mario Remi Yvonne Calomme

The oral administration of bioavailable silicic acid, such as choline-stabilized silicic acid during a period of at least 3 months daily leads to the prevention, inhibition and or treatment of periodontitis and peri-implantatis. The treatment is particularly suitable in combination with appropriate cleaning of the teeth and disinfecting the mouth, by one or more antiseptic and/or antimicrobial agent(s), as carried out at least once and suitably regularly, such as once per year, twice per year, four times per year or even every second month or every month. The treatment may be further enhanced by simultaneous administration of vitamins, trace elements, as well as by administration of a probioticum. Such additional agents may be applied separately, but are preferably incorporated in the formulation of bioavailable silicic acid.